Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress

~ Entered into two new collaborations with top tier animal health companies ~ Entered into a fully funded human health collaboration with a top five global pharmaceutical company ~ Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon ~ Dyadic selected by Frederick National Laboratory to engineer several C1 cell lines to express COVID-19 vaccine candidates ~ Entered into a new fully funded SARS-CoV-2 vaccine research collaboration ~ Filing an S-3 Shelf-registration statement with the SEC and establishing a $50 million At the Money (ATM) offering program ~ Continued strong financial position to advance the Company's programs

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here